恩替卡韦对肝硬化失代偿期、代偿期及慢性乙型肝炎患者的2年抗病毒临床疗效对比  

Comparison of clinical efficacy of entecavir antiviral 2 decompensated liver cirrhosis and compensatory phase patients with chronichepatitis B

作　　者：司慧远[1] 靳雁斌[2] 李晓娟[1] 周平[1] 

机构地区：[1]空军总医院感染内科,北京100142 [2]空军总医院神经内科,北京100142

出　　处：《中国医学前沿杂志（电子版）》2014年第9期33-35,共3页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的研究恩替卡韦治疗肝硬化失代偿期、代偿期及慢性乙型肝炎患者的疗效差异,为临床不同阶段肝硬化和慢性乙型肝炎患者的治疗提供正确指导。方法随机选取本院收治的肝硬化失代偿期患者20例、肝硬化代偿期患者18例及初治慢性乙型肝炎患者38例,三组患者均采用恩替卡韦进行抗病毒治疗,并随访观察。对三组患者治疗前后丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、乙型肝炎病毒e抗原(HBeAg)、HBV DNA定量、胆碱酯酶(CHE)、血清总胆红素(TBIL)、血清白蛋白(ALB)等指标的变化情况进行比较。结果三组患者各指标治疗前比较差异均无显著性(P>0.05)。治疗后三组患者ALT、AST、HBV DNA、TBIL水平均较治疗前明显下降,且治疗前后组内比较差异具有显著性(P<0.05);三组患者HBeAg、CHE、ALB水平与治疗前比较均明显上升,差异具有显著性(P<0.05);三组患者治疗后各指标比较差异均无显著性(P>0.05)。结论临床采用恩替卡韦治疗肝硬化失代偿期、代偿期及慢性乙型肝炎均具有较好的恢复肝功能、降低病毒载量的功效,且治疗各期肝硬化的疗效无显著差异。Objective To study entecavir decompensated cirrhosis and decompensated differences in the treatment of chronic hepatitis B patients, provide proper guidance for the clinical treatment of patients with hepatitis B cirrhosis and different stages. Method Randomly selected our hospital patients with decompensated cirrhosis 20 cases, 18 cases of patients with compensated cirrhosis and chronic hepatitis B patients with newly diagnosed 38 cases, three groups of patients were treated with entecavir antiviral treatment, and follow-up observation. Compared the changes of three groups of patients before and after treatment alanine aminotransferase （ALT）, aspartate aminotransferase （AST）, hepatitis B virus e antigen （HBeAg）, HBV DNA quantitative, cholinesterase （CHE）, serum total bilirubin （TBIL）, serum albumin （ALB） and other indicators. Result Three groups of patients before treatment difference of indicators had no signiifcant （P〉0.05）. Before each indicator and treatment after treatment, ALT, AST, HBV DNA, TBIL levels showed a clear downward trend, and the difference between before and after treatment was signiifcant （P〈0.05） in each group;HBeAg, CHE, ALB levels before treatment comparison showed a clear upward trend, the difference was signiifcant （P〈0.05）;after treatment three groups indexes showed no significant difference （P〉0.05）. Conclusion The clinical entecavir decompensated cirrhosis and decompensated chronic hepatitis B have better recovery of liver function, reduce viral load effect, and for the treatment of liver cirrhosis signiifcant difference.

关 键 词：肝硬化失代偿期 肝硬化代偿期 慢性乙型肝炎 恩替卡韦 

分 类 号：R512.62[医药卫生—内科学]